Retinoid X receptor-antagonistic diazepinylbenzoic acids

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cell Biology

Background:

• Retinoid X receptors (RXRs) and retinoic acid receptors (RARs) are crucial nuclear receptors involved in cell differentiation and gene regulation.
• Dysregulation of retinoid signaling pathways is implicated in various diseases, including cancer.
• Development of selective antagonists for RXRs and RARs is essential for therapeutic intervention.

Purpose of the Study:

• To identify novel retinoid X receptor (RXR) antagonists.
• To investigate the mechanism of action of novel dibenzodiazepine derivatives on RXR and RAR signaling.
• To evaluate the efficacy of these compounds in inhibiting retinoid-induced cell differentiation.

Main Methods:

• Screening of dibenzodiazepine derivatives for inhibitory activity on HL-60 cell differentiation.
• Transactivation assays using retinoic acid receptors (RARs) and RXRs in COS-1 cells.
• Characterization of RXR-selective antagonistic activity of identified compounds.

Main Results:

• Several dibenzodiazepine derivatives, including HX603, HX531, and HX711, were identified as novel RXR antagonists.
• These compounds demonstrated selective antagonistic activity against RXR, inhibiting both RXR homodimer and RAR-RXR heterodimer activation.
• HX603 and related compounds effectively inhibited HL-60 cell differentiation induced by retinoid agonists.

Conclusions:

• Novel dibenzodiazepine derivatives exhibit potent and selective RXR antagonistic activity.
• These compounds represent a distinct class of RXR antagonists, differing from known agents like LG100754.
• The identified RXR antagonists hold promise for therapeutic applications targeting retinoid receptor-mediated pathways.